🚀 Huma Powers Non Interventional Study ProDiGy, Advancing Insomnia Research

Chronic insomnia affects millions, and today we take an important step toward understanding how it is treated in the real world. The first patient in ProDiGy is now enrolled, powered by Huma’s regulated digital health platform.

We are proud to partner with Idorsia on this prospective, non interventional study capturing real-world data on daridorexant across Germany, with the study now expanding into Austria.

Insomnia impacts six percent of the German population and can severely disrupt daily life. Daridorexant offers a novel approach that targets the neurobiology of insomnia to reduce wake drive and improve sleep quality.

Huma’s platform enables fast deployment, compliant data capture, and seamless study operations, helping generate actionable evidence for better care.

We look forward to supporting Idorsia as they push innovation in insomnia research.